The incidence of cancer is increasing every year, which has primarily increased the demand for vaccines in research and development for cancers. The cancer is found damaging the immune system, as cancer cells produce self-antigen. The cancer vaccines thus play a vital role in the maintenance of the immune system, as they are considered to be biological response modifiers.
These cancer vaccines target the infectious agents that may cause cancer, through the production of the antibodies. Cancer vaccines are thus considered to be a new therapy and are not popular, as compared to the other alternative therapeutic drugs. However, cancer vaccines have shown great potential in both preventive and therapeutic ways.
Moreover, healthcare physicians are looking for alternate therapies, due to the huge burden of cancer cases and the side effects of the present therapies. Hence, the market for cancer vaccines is expected to grow at a high rate, during the forecast period.
Key Market Trends
Cervical Cancer Segment is Expected to grow Fastest During the Forecast Period
The increasing prevalence of cervical cancer in the region is considered to be the major driving factor for the market growth. According to Globocan 2018, 11.3 % of cancers are cervical cancer, i. e 119,284 cases have been registered for the year 2018 in Africa. With this huge patient pool and a huge scope of the market, many major players are also looking into investing in the region.
Furthermore, high-quality, sustainable projects, such as in Eldoret (AMPATH Oncology) the work of Hospice Africa Uganda, the collaborations between Crumlin Children’s Hospital (Dublin, Ireland) and the Muhimbili University of Health and Allied Sciences (Dar-es-Salaam) Tanzania, etc. contributes in a positive manner towards cancer control thereby boosting the cancer vaccine market.
The Middle East and Africa Cancer Vaccines Market are moderately competitive with several major players. Some of the strategies implemented include agreements, collaborative models, business expansion, and product developments. Some of the major players are Astellas Pharma Inc., AstraZeneca PLC, Merck & Co. Inc, GlaxoSmithKline, Bristol-Myers Squibb.
Reasons to Purchase this report:
- The market estimate (ME) sheet in Excel format
- 3 months of analyst support